For Healthcare Professionals

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients


About the study

The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  1. Participants with histologically confirmed Grade IV malignant glioma
  2. Previous treatment with radiotherapy and temozolomide (Cohorts 1, 1b and 2 only)
  3. First recurrence of GBM (Cohorts 1, 1b and 2 only)
  4. First diagnosis of GBM with resectable disease (Cohorts 1c Part A only)
  5. First diagnosis of unmethylated MGMT GBM (Cohort 1d and Cohort 1c Part B only)
  6. Karnofsky performance score of 70 or higher


  1. More than 1 recurrence of GBM (Cohorts 1, 1b and 2 only)
  2. Any recurrence of GBM (Cohorts 1c and 1d only)
  3. Presence of extracranial metastatic or leptomeningeal disease
  4. Active, known or suspected autoimmune disease
  5. Clinically significant cardiovascular disease
  6. Prior bevacizumab or other Vascular Endothelial Growth Factor (VEGF) or anti-angiogenic treatment (Cohort 2 only)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Email iconEmail Study Center

Study’s details


Recurrent Glioblastoma




Phase 3

Participants needed


Est. Completion Date

Sep 2023

Treatment type



Bristol-Myers Squibb identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.